Shin Nippon Biomedical Laboratories, Ltd.

TSE:2395 Stock Report

Market Cap: JP¥56.2b

Shin Nippon Biomedical Laboratories Past Earnings Performance

Past criteria checks 1/6

Shin Nippon Biomedical Laboratories has been growing earnings at an average annual rate of 22.5%, while the Life Sciences industry saw earnings growing at 25.6% annually. Revenues have been growing at an average rate of 15.4% per year. Shin Nippon Biomedical Laboratories's return on equity is 16.2%, and it has net margins of 20.9%.

Key information

22.5%

Earnings growth rate

22.5%

EPS growth rate

Life Sciences Industry Growth32.0%
Revenue growth rate15.4%
Return on equity16.2%
Net Margin20.9%
Last Earnings Update31 Mar 2024

Recent past performance updates

Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems

May 21
Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Recent updates

Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems

May 21
Shin Nippon Biomedical Laboratories' (TSE:2395) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 10
Shin Nippon Biomedical Laboratories, Ltd. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Mar 12
Shin Nippon Biomedical Laboratories (TSE:2395) Is Due To Pay A Dividend Of ¥30.00

Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

Feb 27
Shin Nippon Biomedical Laboratories (TSE:2395) Has Affirmed Its Dividend Of ¥30.00

Revenue & Expenses Breakdown

How Shin Nippon Biomedical Laboratories makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSE:2395 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2426,4505,5318,1181,741
31 Dec 2326,7035,5039,033683
30 Sep 2326,6264,6077,806683
30 Jun 2326,8485,4897,520683
31 Mar 2325,0906,0606,894683
31 Dec 2221,1736,2316,050425
30 Sep 2220,1358,0435,648425
30 Jun 2218,7537,2455,178425
31 Mar 2217,7487,1274,908425
31 Dec 2117,6367,4324,803392
30 Sep 2116,0686,0254,566392
30 Jun 2114,9784,8444,417392
31 Mar 2115,1103,6614,482392
31 Dec 2014,9102,4214,574400
30 Sep 2015,1752,8124,692400
30 Jun 2015,0043,2344,764400
31 Mar 2014,5612,5504,840400
31 Dec 1913,4971,9904,308339
30 Sep 1913,1671,9154,175339
30 Jun 1914,6761,5244,656339
31 Mar 1915,6581,9504,865339
31 Dec 1817,337-494,996518
30 Sep 1817,928-9935,251518
30 Jun 1816,937-2,5665,016518
31 Mar 1816,600-3,5555,139518
31 Dec 1717,186-1,0725,081600
30 Sep 1717,7143275,177600
30 Jun 1717,2302605,250600
31 Mar 1717,244-9155,301600
31 Dec 1615,880-1,8215,157815
30 Sep 1615,269-1,2735,282815
30 Jun 1614,922-1,4755,390815
31 Mar 1614,7502,6465,496815
31 Dec 1515,6372,0605,550739
30 Sep 1516,3444015,554739
30 Jun 1517,1641,5465,532739
31 Mar 1517,835-1,3855,579739
31 Dec 1418,058-4175,593747
30 Sep 1417,161-5995,569747
30 Jun 1417,132-1,0745,641747
31 Mar 1416,926-7545,449747
31 Dec 1316,993-1,4435,613577
30 Sep 1317,513-1,1855,483577

Quality Earnings: 2395 has a high level of non-cash earnings.

Growing Profit Margin: 2395's current net profit margins (20.9%) are lower than last year (24.2%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2395's earnings have grown significantly by 22.5% per year over the past 5 years.

Accelerating Growth: 2395's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 2395 had negative earnings growth (-8.7%) over the past year, making it difficult to compare to the Life Sciences industry average (-18.1%).


Return on Equity

High ROE: 2395's Return on Equity (16.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.